Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA") and insomnia, today announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC ("SPCVA"), a growing Florida-based cardiology practice with approximately 30,000 patients of record, to support the formation and operation of AIM Florida, LLC ("AIM Florida"), a physician-aligned management services organization intended to expand access to integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease ("CVD") patients in Florida who also suffer from OSA and insomnia.